Skip to main content

Psoriatic Arthritis

Dr. John Cush
@RheumNow
Two Prescriptions, One Patient Obesity, in particular in PsA was widely covered at #ACR26. In the Swiss SCQM registry, 63.6% of 2,087 patients with PsA were overweight or obese, compared with 31% overweight and 12% obese in the Swiss population, and higher BMI tracked disease https://t.co/Ys5wTvQ2r9
Dr. John Cush
@RheumNow
Falls Hide in Plain Sight in Rheumatic Disease A patient with arthritis pitches forward onto her knees and wrists while bending to grab something. Another time she tries to get up and lands on the bed. Another time she uses a chair to lower herself to the floor. By the World https://t.co/kmmaRxhII0
Dr. John Cush
@RheumNow
Biologic Dosing and Obesity A 46-year-old with pSa and a BMI of 38 still has active disease on adalimumab (Humira) 40 mg every other week. What do you do? Stephen Balevic, MD, PhD, discusses this question in "Prescribing the Right Dose: How Obesity Alters Drug https://t.co/0SGQGs32U2
Dr. John Cush
@RheumNow
Are GLP-1s Doing More Than Shrinking Waistlines in PsA? In abstract #0373, Pankti Mehta and colleagues examined patients from a longitudinal PsA cohort who initiated GLP-1 receptor agonist or dual GIP/GLP-1 therapy and compared them with matched controls. Baseline body mass https://t.co/FGCszLnS4N
Antoni Chan MD (Prof)
@synovialjoints
ACR26 summary, AI and documentation: errors on all five AI platforms tested against guidelines, and cDAPSA documented in 4.9% of PsA records @rheumnow #ACR26 Abstract#0869 Abstract#1348
Antoni Chan MD (Prof)
@synovialjoints
ACR26 summary, obesity in PsA: 81.8% prevalence of overweight or obesity in a US cohort, lower ACR50 at higher BMI on bimekizumab, and higher ACR50 with ixekizumab plus tirzepatide at 52 weeks. @rheumnow #ACR26 Abstract#2015 Abstract#1305 Abstract#2942
Audrey Gibson
@Gibson_RheumPAC
Merola et al. (TOGETHER-PsA): The most provocative PsA finding at ACR2026? Treating inflammation alone may leave a modifiable contributor to symptoms and outcomes unaddressed. TOGETHER-PsA offers randomized evidence to discuss. @rheumnow #ACR2026 Abstract#2942
Audrey Gibson
@Gibson_RheumPAC

TOGETHER-PsA by Merola et al may be a practice-changing obesity story. Adding tirzepatide to ixekizumab improved joint outcomes at 52 weeks. Treating inflammation alone may not be enough for some patients with PsA. @rheumnow #ACR2026 #ACRBest Abstract#2942

Audrey Gibson
@Gibson_RheumPAC
Merola et al. (TOGETHER-PsA): In PsA + obesity, adding tirzepatide to ixekizumab improved ACR50 and several disease-activity measures at week 52. Randomized data; open-label design. @rheumnow #ACR2026 Abstract#2942
Audrey Gibson
@Gibson_RheumPAC

Merola et al, TOGETHER-PsA: At 52 weeks, ACR50 was 43.7% with ixekizumab + tirzepatide vs 15.7% with ixekizumab alone. A 28-point difference! Is addressing obesity becoming essential to optimal PsA care? @rheumnow #ACR2026 #ACRBest Abstract#2942

×